Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sports guy, Auger08, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 12/20/2014 12:58:12 PM - Followers: 636 - Board type: Free - Posts Today: 31


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
News News Alert: Current Report Filing (8-k) 12/19/2014 04:32:35 PM
PostSubject
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#78031   Discover magazine story of the year voting. Wopsal101 12/20/14 12:58:12 PM
#78030   Nice post! One error though. SMD Wopsal101 12/20/14 12:29:09 PM
#78029   There are a few things that I would homeslice10 12/20/14 12:09:19 PM
#78028   He is very pessimistically optimistic. Meaning he Wopsal101 12/20/14 12:03:53 PM
#78027   I have a question for Hopalongstocks: elysse1kittycat 12/20/14 11:56:04 AM
#78026   OCAT = BUY more while you can. .. calm61 12/20/14 11:29:36 AM
#78025   Wrong. There is NO "lock up period" to Hopalongstocks 12/20/14 10:59:55 AM
#78024   All 32 million shares have been diluted and LittleDutchDenny 12/20/14 10:44:19 AM
#78023   OCAT can_rebuild your retina, this is better_than_curing. rumper 12/20/14 10:44:12 AM
#78022   HUH?? "So with the posting of the company's Trader Joey 12/20/14 10:32:38 AM
#78021   Juno Therapeutics just IPO'd at $3 billion. Wopsal101 12/20/14 10:31:10 AM
#78020   HUH? All this 8-K filing was IMO, was Trader Joey 12/20/14 10:26:55 AM
#78019   Monday could go down but it won't matter Trader Joey 12/20/14 10:20:36 AM
#78018   "So with the posting of the company's presentation. Hopalongstocks 12/20/14 09:18:12 AM
#78017   "What a con"??? "All 32 million shares have Hopalongstocks 12/20/14 09:07:21 AM
#78016   If you look at the company slides, up Wopsal101 12/20/14 08:54:07 AM
#78015   So with the posting of the company's presentation. interstate 12/20/14 08:32:05 AM
#78014   Number 9, I remember watching him play in Gastrodamas 12/20/14 07:51:21 AM
#78013   Umm... I'm by no means an SEC expert, permanentflux 12/20/14 07:42:12 AM
#78012   All hype this downgrade is short lived the boulder1 12/20/14 07:34:47 AM
#78011   What a con. This company never seported Ocat boulder1 12/20/14 07:24:29 AM
#78010   Amazingly, when an analyst writes something with a mind1 12/20/14 06:36:40 AM
#78006   When Dr. Lanza is here there is no crawford2012 12/20/14 01:54:44 AM
#78005   Maybe the SEC, FINRA & Nasdaq have new crawford2012 12/20/14 12:57:31 AM
#78004   elllk thank you for taking the time to crawford2012 12/20/14 12:49:03 AM
#78003   Yes their pt have been waay off as aberlowi 12/20/14 12:36:22 AM
#78002   OT: GORDIE HOWE'S FAMILY REPORTS 'MIRACULOUS' IMPROVEMENT FOLLOWING elllk 12/20/14 12:35:08 AM
#78001   Hmmm-aren't we about due for a new Groundhog elysse1kittycat 12/20/14 12:00:07 AM
#78000   One might choose to be happy about patients chuckanutman 12/19/14 11:35:59 PM
#77999   Maxim put a price target on this company chuckanutman 12/19/14 11:06:49 PM
#77998   We'll said! Thanks FVH! AyeEye 12/19/14 11:06:00 PM
#77997   Excellent excellent post Farv. This is a downgrade aberlowi 12/19/14 11:05:29 PM
#77996   My 'read' of the Maxim analyst supposed downgrade farviewhill 12/19/14 10:29:20 PM
#77995   Yes I did notice...it appears that the up crawford2012 12/19/14 10:07:35 PM
#77994   Post of the day Gastrodamas. There is chuckanutman 12/19/14 09:25:36 PM
#77993   Maxim group, now that I think about it Gastrodamas 12/19/14 09:18:26 PM
#77992   Said low 6.00 Maxim will see to it. Gastrodamas 12/19/14 08:30:41 PM
#77991   Figures Gastrodamas 12/19/14 08:23:25 PM
#77990   So did I, OTC. Gastrodamas 12/19/14 08:18:02 PM
#77989   On the other hand, here is another analysis elysse1kittycat 12/19/14 06:49:05 PM
#77988   Since these guys are usually wrong I'd guess homeslice10 12/19/14 06:03:55 PM
#77987   http://www.smarteranalyst.com/2014/12/19/maxim-downgrades-ocata-therapeutics-may manfromjax 12/19/14 05:56:17 PM
#77986   8K..Active dialogue with NASDAQ...but there are a couple Trader Joey 12/19/14 05:27:45 PM
#77985   Thank you for sharing this very valuable piece crawford2012 12/19/14 05:17:39 PM
#77984   8K is now out.......... Trader Joey 12/19/14 04:37:32 PM
#77983   This stock always reacts the opposite way I anselab 12/19/14 04:32:47 PM
#77982   Wow opposite happened. I expected to get steam Auger08 12/19/14 04:01:13 PM
#77981   Friday.... 3:30pm is almost paint the tape time... Trader Joey 12/19/14 03:25:48 PM
#77980   All about the offering price. interstate 12/19/14 02:00:20 PM
#77979   When is a buying opportunity not a buying Auger08 12/19/14 01:58:43 PM
PostSubject